Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telomerase inhibitors as anticancer therapy.

Masaharu Akiyama1, Teru Hideshima, Nikhil C Munshi

  • 1Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed
Summary

Telomerase inhibitors offer a novel cancer therapy by targeting high telomerase levels in tumors. Inhibiting telomerase induces tumor cell death and enhances sensitivity to other cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.

Analytical chemistry·2014
Same author

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Blood·2014
Same author

Daratumumab granted breakthrough drug status.

Expert opinion on investigational drugs·2014
Same author

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

International journal of oncology·2014
Same author

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Blood·2014
Same author

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Nature communications·2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Telomerase is highly expressed in most tumor cells, unlike normal somatic cells.
  • Telomerase maintains telomere length, crucial for tumor cell proliferation and chromosomal stability.
  • Shortening telomeres via telomerase inhibition can induce tumor cell senescence and apoptosis.

Purpose of the Study:

  • To review the basic biology of telomeres and telomerase.
  • To explore telomerase inhibition as a therapeutic strategy for cancer treatment.
  • To discuss the potential of telomerase inhibitors as an adjuvant therapy.

Main Methods:

  • Literature review of telomere and telomerase biology.
  • Analysis of telomerase inhibition mechanisms in cancer cells.

Related Experiment Videos

  • Discussion of therapeutic implications and limitations.

    • Main Results:

    • Telomerase activation is essential for sustained tumor cell proliferation.
    • Inhibition of telomerase leads to telomere shortening, inducing growth arrest and apoptosis.
    • Telomerase inhibitors may increase tumor cell susceptibility to conventional anticancer agents.

    Conclusions:

    • Telomerase inhibitors represent a promising cancer-specific therapeutic approach.
    • Potential limitations include a lag phase between inhibition and cellular effects.
    • Further research into telomerase inhibition is warranted for developing novel cancer treatments.